See more : Canadian North Resources Inc. (CNRSF) Income Statement Analysis – Financial Results
Complete financial analysis of Eiger BioPharmaceuticals, Inc. (EIGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eiger BioPharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ecoark Holdings, Inc. (ZEST) Income Statement Analysis – Financial Results
- BioQuest Corp. (BQST) Income Statement Analysis – Financial Results
- Globe Trade Centre S.A. (GBCEY) Income Statement Analysis – Financial Results
- Biome Grow Inc. (BIOIF) Income Statement Analysis – Financial Results
- Inspirato Incorporated (ISPO) Income Statement Analysis – Financial Results
Eiger BioPharmaceuticals, Inc. (EIGR)
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.77M | 13.48M | 12.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 24.00K | 1.84M | 745.00K | 645.00K | 486.00K | 54.00K | 41.00K | 23.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.75M | 11.65M | 11.40M | -645.00K | -486.00K | -54.00K | -41.00K | -23.00K | -11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 99.85% | 86.38% | 93.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.33M | 75.28M | 64.44M | 41.59M | 51.79M | 37.09M | 29.52M | 33.01M | 21.96M | 22.68M | 16.93M | 13.31M | 4.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.20M | 29.11M | 23.90M | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Other Expenses | 87.00K | -963.00K | 46.49M | -12.00K | -15.00K | -12.00K | 186.00K | -277.00K | 5.00K | -835.00K | 25.00K | 147.00K | 152.00K |
| Operating Expenses | 87.54M | 104.39M | 88.34M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Cost & Expenses | 87.56M | 106.22M | 89.08M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Interest Income | 2.21M | 1.08M | 158.00K | 704.00K | 2.07M | 997.00K | 410.00K | 0.00 | 65.00K | 118.00K | 69.00K | 35.00K | 7.00K |
| Interest Expense | 5.47M | 4.13M | 3.56M | 3.59M | 3.41M | 2.33M | 1.52M | 690.00K | 2.30M | 741.00K | 59.00K | 108.00K | 1.12M |
| Depreciation & Amortization | 750.00K | 119.00K | 46.65M | 1.34M | 2.54M | 54.00K | 41.00K | 23.00K | 504.00K | 153.00K | 67.00K | 64.00K | 73.00K |
| EBITDA | -68.74M | -92.62M | -76.94M | -60.81M | -66.36M | -50.06M | -40.92M | -46.40M | -33.82M | -33.02M | -19.80M | -15.70M | -5.79M |
| EBITDA Ratio | -435.81% | -686.90% | -249.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.79M | -92.74M | -76.94M | -62.15M | -68.90M | -51.05M | -41.52M | -46.12M | -42.18M | -33.02M | -19.96M | -15.95M | -6.03M |
| Operating Income Ratio | -455.12% | -687.78% | -633.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.17M | -4.01M | 43.09M | -2.90M | -1.35M | -1.34M | -928.00K | -967.00K | -2.23M | -835.00K | -127.00K | 74.00K | -965.00K |
| Income Before Tax | -74.96M | -96.75M | -33.85M | -65.05M | -70.25M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.09M | -15.87M | -6.99M |
| Income Before Tax Ratio | -475.22% | -717.54% | -278.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 6.00K | 23.00K | 64.00K | 3.58M | 3.39M | 985.00K | 1.67M | 390.00K | 2.31M | -153.00K | -12.00K | 101.00K | 1.28M |
| Net Income | -74.96M | -96.78M | -33.92M | -68.63M | -73.64M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.00M | -15.72M | -6.99M |
| Net Income Ratio | -475.26% | -717.71% | -279.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EPS Diluted | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| Weighted Avg Shares Out | 1.48M | 1.39M | 34.63M | 29.88M | 24.43M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
| Weighted Avg Shares Out (Dil) | 1.48M | 1.39M | 34.63M | 29.88M | 24.50M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
Healthcare stocks fade as obesity-drug optimism fades
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries...
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria Eiger to receive $500,000 approval milestone payment from AnGes Zokinvy approved in the U.S. (2020), 30 European countries...
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of...
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. According to a press release from the company, it has discontinued its Phase 3 LIMT-2 study.
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda...
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will...
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian, MD, PhD,...
Eiger BioPharmaceuticals: Wall Street Has High Expectations For Faltering Battleground Stock
Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way.
EIGR Stock: 23.53% Surge Explanation
The stock price of Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) surged by 23.53% today. This is why.
Source: https://incomestatements.info
Category: Stock Reports